Enhancing GD2 CAR T-cell therapy with IGF-1R blockade: Are DIPG CAR T cells ready for combinatorial therapy? is a research paper published in Neuro-Oncology (2022). On theSindex it has a DataRank of 0.344. It has been cited 5 times, with 5 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0.0752
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
NINDS
Grant: R01-NS124607
NINDS
Grant: R01-NS119231
Department of Defense
Grant: CA201129P1
NINDS NIH HHS
Grant: R01 NS124607
NINDS NIH HHS
Grant: R01 NS119231
National Institutes of Health
Grant: 5R01NS119231-04
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma
National Institutes of Health
Grant: 5R01NS124607-03
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
University of Michigan Chad Carr Pediatric Brain Tumor Center
Pediatric Brain Tumor Foundation
NIH
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals